Arcus Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcus Biosciences (RCUS).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$36Upside to Avg. PT+23.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 8, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
Aug 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
Jul 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
Jun 4, 2026	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
May 18, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
May 11, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
May 7, 2026	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
Apr 2, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
Mar 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45
Mar 2, 2026	Leerink Partners	Geoffrey Porges	PT Raise	Outperform	$36→$49
Mar 2, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$32
Feb 12, 2026	Wells Fargo	Eva Fortea Verdejo	Downgrade	Overweight→Equal-Weight	$30→$23
Jan 13, 2026	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$16→$28
Jan 8, 2026	Morgan Stanley	Terence Flynn	Downgrade	Overweight→Equal-Weight	$23→$20
Dec 12, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$28→$32
Nov 28, 2025	B of A Securities	Jason Zemansky	PT Raise	Neutral	$17→$26
Oct 30, 2025	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$14→$16
Oct 29, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$54→$56
Oct 29, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$24→$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.

Benzinga Newsdesk

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.

Vandana Singh

PRO
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.

Benzinga Newsdesk

PRO
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

Truist Securities analyst Supawat Thongthip assumes Arcus Biosciences (NYSE:RCUS) with a Buy rating and raises Price Target to $35.

Benzinga Newsdesk

Arcus Biosciences Inc

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

PRO
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

PRO
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

People Also Watch

People Also Watch

Arcus Biosciences Inc

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PROWells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

PROHC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

PROTruist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

PRO
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45

PRO
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35